# LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

Source: https://onco.cc/trials/nct06232408/  
OnCo record `nct06232408` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of RP-1664 run by Repare Therapeutics, terminated.

## Summary

LIONS (PLK4 Inhibitor in Advanced Solid Tumors) is a phase 1 interventional study registered as NCT06232408 by Repare Therapeutics, with 29 participants enrolled, started 2024-02-14. Conditions recorded: Advanced Solid Tumor. Interventions recorded: RP-1664.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06232408
- Phase: 1
- Setting: Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors
- Sponsor: Repare Therapeutics
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT06232408: https://clinicaltrials.gov/study/NCT06232408

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [RP-1664](https://onco.cc/drugs/rp-1664/)
- companies: [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06232408.json